+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pemetrexed"

Non-Small Cell Lung Cancer (NSCLC) Market Report 2025 - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 60 Pages
  • Global
From
Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Pemetrexed + cisplatin Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Pemetrexed is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of antifolate, meaning it works by blocking the action of folic acid, which is essential for cancer cells to grow and divide. Pemetrexed is usually used in combination with other chemotherapy drugs, such as cisplatin or carboplatin. It is also used to treat mesothelioma, a type of cancer caused by exposure to asbestos. Pemetrexed is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and mesothelioma. It is available in both intravenous and oral formulations. The intravenous formulation is administered in combination with other chemotherapy drugs, while the oral formulation is used as a single agent. Pemetrexed is marketed by several pharmaceutical companies, including Eli Lilly, Bristol-Myers Squibb, and Merck. It is also available as a generic drug in some countries. Show Less Read more